1stOncology™: Cancer Intelligence Service – Page 5677 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

On March 17, 2023 Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, reported its financial results for the fourth quarter and year ended December 31, 2022 and provided a business update (Press release, Gossamer Bio, MAR 17, 2023, View Source [SID1234628986]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Clinical-Stage Product Candidate Updates
Seralutinib (GB002): Inhaled PDGFR, CSF1R and c-KIT Inhibitor for Pulmonary Arterial Hypertension (PAH)
•Upon completion of the 24-week blinded portion of the Phase 2 TORREY Study, patients were able to enroll into an open-label extension trial. We anticipate reporting results from this ongoing open-label extension trial in the middle of 2023.
• We expect to commence a Phase 3 PAH clinical trial in the second half of 2023. The planned Phase 3 clinical trial will be a randomized, double-blind, placebo-controlled, global clinical trial in PAH patients. Patients will be randomized to receive either seralutinib or placebo, in addition to their background PAH therapies.
• Based on FDA feedback, we expect to test a single dose of 90 mg twice daily in the planned PAH Phase 3 clinical trial, and we expect the primary endpoint of the trial to be change in six-minute walk distance from baseline. However, the final trial design is subject to further feedback from global regulatory authorities.

GB5121: Oral, CNS-Penetrant BTK Inhibitor for Primary CNS Lymphoma (PCNSL)
•Based upon the benefit / risk profile observed to date and a prioritization of resources to support the seralutinib program, Gossamer has decided to pause enrollment in the Phase 1b/2 STAR CNS study.
•Gossamer plans to discuss available data with the study’s Data Review Committee to determine next steps.

Financial Results for Quarter and Full Year Ended December 31, 2022
•Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of December 31, 2022, were $255.7 million. As a result, we expect our current cash, cash equivalents and marketable securities will be sufficient to fund operating and capital expenditures into the second half of 2024.
•Research and Development (R&D) Expenses: For the quarter ended December 31, 2022, R&D expenses were $41.5 million compared to R&D expenses of $40.9 million for the same period in 2021. R&D expenses for the full year ended December 31, 2022, were $170.9 million compared to $170.3 million for the full year ended December 31, 2021.
•General and Administrative (G&A) Expenses: For the quarter ended December 31, 2022, G&A expenses were $12.8 million compared to $10.7 million for the same period in 2021. G&A expenses for the full year ended December 31, 2022, were $47.6 million compared to $45.8 million for the full year ended December 31, 2021.
•Net Loss: Net loss for the three months ended December 31, 2022, was $55.8 million, or $0.59 per share, compared to a net loss of $56.3 million, or $0.74 per share, for the same period in 2021. Net loss for the full year ended December 31, 2022, was $229.4 million, or $2.71 per share compared to a net loss of $234.0 million, or $3.13 per share, for the full year ended December 31, 2021.

Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update

On March 17, 2023 Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, reported the company will discuss its fourth quarter and full-year 2022 financial results and provide a business update on Friday, March 31, 2023, at 8:00 am Eastern Time (Press release, Chemomab, MAR 17, 2023, View Source [SID1234628984]).

During the event, Chemomab’s management team will review fourth quarter and full-year 2022 performance, discuss recent and upcoming developments and conduct a live question-and-answer session.

A replay of the call will be available on Chemomab’s website for 90 days at www.chemomab.com.

Live Webcast and Conference Call at 8:00 am Eastern Time, Friday, March 31, 2023

Click this Webcast link to access the live webcast or replay.

The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events.

Conference Call Access via Telephone

US Investors:

+1 (877) 407-9208

International Investors:

+1 (201) 493-6784

Conference Passcode:

#13735392

Or click on Call me for instant telephone access to the event

Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.

CD25-ApDC initial in vitro study results..CD25 binding ability, inhibition ability, cytotoxicity, etc. confirmed

On March 16, 2023 Aptamer Sciences, an aptamer platform company, reported that it will present research results on the ‘CD25-ApDC’ immunotherapy (IO) at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (AACR 2023), which will be held from April 14th (Press release, Aptamer Sciences, MAR 16, 2023, View Source;idx=236 [SID1234641620]).

Aptamer Science’s theme at this AACR (Free AACR Whitepaper) is ‘Human CD25-targeted aptamer-drug conjugate (CD25-ApDC) depletes and blocks regulatory T cells’. The research results will be announced.

Aptamer Science’s CD25-ApDC immunotherapy is a concept that specifically binds to CD25 on regulatory T cells (Treg) in tumors to prevent cancer cells from evading the body’s immune system.

In particular, CD25-ApDC not only selectively suppresses the function of Tregs, but also promotes immune function by inducing the activation of cytotoxic T cells (effector T cells, Teff) and antigen presenting cells that prevent tumor growth. The company explains that it also does this.

According to the AACR (Free AACR Whitepaper) abstract of Aptamer Science CD25-ApDC, Tregs suppress anti-tumor immune responses and promote tumor development and progression.

Additionally, in various cancer types, high infiltration of Tregs is associated with poor survival rates. Aptamer Science is developing CD25-ApDC as a strategy to target Tregs associated with tumor promotion.

In this study, Aptamer Science evaluated the binding affinity, internalization rate, and antagonist effect on CD25 of the CD25-specific aptamer.

In addition, the in vitro cytotoxicity of CD25-ApDC prototype-ApDC was evaluated.

As a result of the evaluation, the binding affinity of the aptamer to CD25 was confirmed to be 4.64nM. In the Treg-like cell line (Karpas299), the internalization half-time of the aptamer was found to be 9.9 minutes (95% CI: 8.2~12.6).

In addition, it was confirmed that it functions as an antagonist for CD25, as the IL-2R-STAT5 signaling pathway was inhibited by aptamer treatment.

When prototype-ApDC was treated with a Treg-like cell line and a T-cell lymphoma cell line (HuT78) in co-culture, the Treg-like cell line was shown to be specifically depleted.

The CD25-ApDC immune anti-cancer drug research presented at this conference has been selected as a research project to expand the new drug base of the National New Drug Development Project hosted by the Korea New Drug Development Foundation (KDDF), and mechanism research and animal model evaluation are currently in progress at the lead material stage.

Lee Dae-gyeon, head of Aptamer Science Research and Development Division, said, "I believe that the presentation at this global conference will be an opportunity to verify the feasibility and competitiveness of aptamer-based immunotherapy research."

"Based on this, we plan to secure momentum for developing treatments and speed up development to conclude early partnerships in the future."

Meanwhile, Aptamer Science has been developing an aptamer-drug conjugate (ApDC) anticancer drug based on aptamer platform technology, and is preparing to enter the clinical stage within the year for ‘AST-201’, a GPC3 ApDC being developed as a liver cancer treatment.

In addition to GPC3, Aptamer Science is developing follow-up pipelines for targets such as Trop2 and EGFRvIII.

Go to article: Aptamer Science, ‘CD25-ApDC’ IO "AACR announcement"

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On March 17, 2023 Geron Corporation (Nasdaq: GERN) reported that it has granted non-statutory stock options to purchase an aggregate of 490,630 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company (Press release, Geron, MAR 16, 2023, View Source [SID1234628985]).

The stock options were granted on March 15, 2023 at an exercise price of $2.62 per share, which is equal to the closing price of Geron common stock on the date of grant. Stock options representing an aggregate of 460,000 shares have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment for the respective employees and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. Stock options representing an aggregate of 30,630 shares have a 10-year term and vest in full upon achievement of certain regulatory milestones, subject to continued employment with Geron through the applicable vesting dates. All of the stock options were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron’s 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.

Exscientia to Report Full Year 2022 Financial Results on March 23, 2023

On March 16, 2023 Exscientia plc (Nasdaq: EXAI) reported financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the open of U.S. markets (Press release, Exscientia, MAR 16, 2023, View Source [SID1234628970]). The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results.

A webcast of the live call can be accessed by visiting the "Investors and Media" section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under "Events and Presentations" in the "Investors and Media" section of the Exscientia website.